Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1681 to 1695 of 9045 results

  1. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  2. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)

    Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.

  3. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

  4. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

  5. High intensity focused ultrasound ablation for pain caused by bone metastases

    Topic prioritisation

  6. Transcutaneous electrical stimulation of the upper airway dilator muscles for obstructive sleep apnoea

    Topic prioritisation

  7. Polydioxanone stents for the therapy of Tracheal stenosis: adults

    Topic prioritisation

  8. Intravenous infusion of mesenchymal stromal cells in patients with severe recalcitrant psoriasis

    Topic prioritisation

  9. Lateral orbital decompression

    Topic prioritisation

  10. Selective internal radiation therapy for unresectable colorectal metastases in the liver

    Topic prioritisation

  11. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]

    Topic prioritisation

  12. High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]

    Topic prioritisation

  13. TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 [TSID11807]

    Topic prioritisation

  14. ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]

    Topic prioritisation